| 000 | 01820 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518063634.0 | ||
| 264 | 0 | _c20210616 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a2374-2445 | ||
| 024 | 7 |
_a10.1001/jamaoncol.2019.3343 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Joyce F | |
| 245 | 0 | 0 |
_aAssessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. _h[electronic resource] |
| 260 |
_bJAMA oncology _c12 2019 |
||
| 300 |
_a1731-1738 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aBevacizumab _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Ovarian Epithelial _xdrug therapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 |
_aNivolumab _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aHerold, Christina | |
| 700 | 1 | _aGray, Kathryn P | |
| 700 | 1 | _aPenson, Richard T | |
| 700 | 1 | _aHorowitz, Neil | |
| 700 | 1 | _aKonstantinopoulos, Panagiotis A | |
| 700 | 1 | _aCastro, Cesar M | |
| 700 | 1 | _aHill, Sarah J | |
| 700 | 1 | _aCurtis, Jennifer | |
| 700 | 1 | _aLuo, Weixiu | |
| 700 | 1 | _aMatulonis, Ursula A | |
| 700 | 1 | _aCannistra, Stephen A | |
| 700 | 1 | _aDizon, Don S | |
| 773 | 0 |
_tJAMA oncology _gvol. 5 _gno. 12 _gp. 1731-1738 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamaoncol.2019.3343 _zAvailable from publisher's website |
| 999 |
_c30189785 _d30189785 |
||